血管內皮生長因子（Vascular Endothelial Growth Factor）抑制劑之腎毒性

Nephrotoxicity of Vascular Endothelial Growth Factor Inhibitors

童郁琇(Yu-Hsiu Tung) ； 劉淑貞(Shu-Chen Liu)

《臺灣臨床藥學雜誌》 30卷3期 (2022/07) Pp. 217-224

https://doi.org/10.6168/FJCP.202207_30(3).0004

摘要

癌症病人往往因為腫瘤自身或治療而增加腎臟疾病風險。血管內皮生長因子抑制劑（vascular endothelial growth factor inhibitors, VEGF inhibitors）的出現顯著改善病人預後，但也同時可能造成腎毒性，其中高血壓和蛋白尿被認為是主要的副作用，雖然大部分情況都屬於輕度可耐受，但它們的出現也代表一種警訊，而且，目前對於其機轉以及治療策略也尚未清楚。因此，治療期間之腎功能監控是非常重要的，可以及時辨識不良反應和給予適當處理。本文將依據目前文獻探討，VEGF抑制劑之常見腎毒性的發生率、機轉以及處理方式。

關鍵字

血管內皮生長因子抑制劑 ； 腎毒性 ； 高血壓 ； 蛋白尿

並列摘要

Patients with cancer often increase the risk of kidney disease because of the tumor itself or the treatment. The emergence of vascular endothelial growth factor inhibitors (VEGF inhibitors) has significantly improved the prognosis of patients, but it may also cause nephrotoxicity, and hypertension and proteinuria are considered to be the main side effects. Although most of the conditions are mildly tolerable, those side effects also represent a warning sign, and currently its mechanism and treatment strategy are not yet clear. Therefore, it is very important to monitor the renal function during the treatment, so that adverse reactions can be identified in time and given the appropriate treatment. In this article, we will discuss the incidence, mechanisms, and treatment of common nephrotoxicity for VEGF inhibitors based on the current literature review.

並列關鍵字

VEGF Inhibitors ； Nephrotoxicity ； Hypertension ； Proteinuria